Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and related comorbidities, including chronic kidney disease and obstructive sleep apnea [3] Group 1: Stock Option Award - On November 24, 2025, the Compensation Committee of Mineralys granted an inducement stock option award covering 146,000 shares to a new non-executive employee [1] - The stock option will vest over a four-year period, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, contingent on continued service [2] - The award is part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting new employees [2] Group 2: Company Overview - Mineralys Therapeutics is based in Radnor, Pennsylvania, and was founded by Catalys Pacific [3] - The company's initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor [3]